ORBIS (Open Research Biopharmaceutical Internships Support) – building bridges between academia and pharmaceutical industry to improve drug development

Authors

DOI:

https://doi.org/10.20883/medical.419

Keywords:

drug discovery and design, pharmaceutical formulation, research and development, solid state materials, pharmaceutical technology, biomedical analysis

Abstract

Open Research Biopharmaceutical Internships Support (ORBIS) is an international, Horizon 2020 project funded by Maria Skłodowska-Curie Actions, Research and Innovation Staff Exchange (RISE) programme. Six academic institutions and four pharmaceutical companies from seven countries cooperate with the aim to improve the preclinical pathway of medicine development through increased Research and Development (R&D) productivity, especially focusing on processes and technologies which address the challenge of poor drug bioavailability. The RISE scheme supports secondments, meaning that early stage and experienced researchers are sent to consortium partner institutions to advance studies on pharmaceutical preformulation, dosage forms and drug delivery systems and methods of biopharmaceutical evaluation. The ORBIS project enables secondees to gain news skills and develop their competences in an international and intersectoral environment, strengthening the human capital and knowledge synergy in the European pharmaceutical R&D sector.

Downloads

Download data is not yet available.

Author Biography

Janina Lulek, Chair and Department of Pharmaceutical Technology, Faculty of Pharmacy, Poznan University of Medical Sciences, Poznan, Poland

Chair and Department of Pharmaceutical Technology
Poznan University of Medical Sciences
Grunwaldzka 6 st.
60-780 Poznan, Poland,
jlulek@ump.edu.pl
phone + 48 61 854 66 60, fax +48 61 854 66 66

References

Guideline on bioanalytical method validation. https://www.ema.europa.eu/en/bioanalytical-method-validation. Accessed 2020 March 11.

Kaza M, Karaźniewicz-Łada M, Kosicka K, Siemiątkowska A, Rudzki PJ. Bioanalytical method validation: new FDA guidance vs. EMA guideline. Better or worse?. Journal of Pharmaceutical and Biomedical Analysis. 2019 02;165:381-385. https://doi.org/10.1016/j.jpba.2018.12.030

Rudzki PJ, Milanowski B, Tajber L, Garbacz G, Jakubowska E, Rychter M, Kutner A, Lulek J. Otwarcie międzynarodowego i międzysektorowego projektu ORBIS (Horyzont 2020). Polskie Towarzystwo Farmaceutyczne. 2018 Jul;74(7):413-6.

Rudzki PJ, Biecek P, Kaza M. Incurred Sample Reanalysis: Time to Change the Sample Size Calculation?. The AAPS Journal. 2019 02 11;21(2). https://doi.org/10.1208/s12248-019-0293-2

Grynkiewicz G, Maruszak W. Open Space Knowledge and Data and Their Influence on Natural Products Based Self-Medication Trends. Cancer Studies and Therapeutics. 2019 Aug;4(3):1-3.

Hincker A, Frey K, Rao L, Wagner-Johnston N, Ben Abdallah A, Tan B, Amin M, Wildes T, Shah R, Karlsson P, Bakos K, Kosicka K, Kagan L, Haroutounian S. Somatosensory predictors of response to pregabalin in painful chemotherapy-induced peripheral neuropathy. PAIN. 2019 08;160(8):1835-1846. https://doi.org/10.1097/j.pain.0000000000001577

ORBIS project website. https://orbisproject.eu. Accessed 2020 March 17.

How to Cite

1.
Jakubowska E, Davin S, Dumicic A, Garbacz G, Juppo A, Michniak-Kohn B, Rudzki PJ, Smułek W, Strachan C, Syarkevych O, Tajber L, Lulek J. ORBIS (Open Research Biopharmaceutical Internships Support) – building bridges between academia and pharmaceutical industry to improve drug development. JMS [Internet]. 2020 Mar. 31 [cited 2022 Dec. 2];89(1):e419. Available from: https://jms.ump.edu.pl/index.php/JMS/article/view/419

Issue

Section

Thousand words about...
Received 2020-04-14
Published 2020-03-31